Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network
PARSIPPANY, NJ, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides beneficial molecular diagnostic tests and pathology services that improve patient diagnosis and management, announced today that the Company will participate in several local events in support of the following patient advocacy groups: Lustgarten Foundation Pancreatic Cancer Research (The Lustgarten Foundation), Thyroid, Head and Neck Cancer (THANC) Foundation, and Pancreatic Cancer Action Network (PanCAN).
The Lustgarten Foundation and PanCAN are global organizations striving to advance scientific and medical research for pancreatic cancer in order to improve the lives of patients and their families. In their fight against one of the world’s deadliest cancers, the organizations provide funding for research as well as patient services, advocacy and community engagement. To support these organizations, Interpace employees will participate in the following events:
- Lustgarten Foundation Pancreatic Cancer Research Walk on September 23, 2018
- PanCAN Purple Stride Run/Walk on October 13, 2018
The THANC Foundation is committed to supporting research and education for the advancement of early detection and treatment of thyroid and head and neck cancer. As one of the largest private funders of research in the U.S. for these types of cancer, the organization also aims to advance new therapies and improve patient quality of life by alleviating suffering and functional impairment. To support the THANC Foundation, Interpace employees will participate in the THANC Foundation Charitable Outing on September 24, 2018.
“At Interpace, we operate everyday with the intent of advancing patient care through molecular diagnostic testing, which can allow for earlier and more accurate diagnosis of grievous diseases such as pancreatic and thyroid cancer,” said Jack Stover, CEO of Interpace. “To further these efforts, the Interpace community is excited to be part of local events hosted by PanCAN, the Lustgarten Foundation, and the THANC Foundation organizations that share our focus of serving and making a meaningful impact on lives of patients and their families.”
About the Pancreatic Cancer Action Network (PanCAN)
The Pancreatic Cancer Action Network (PanCAN) is accelerating the pace of research progress for one of the world’s deadliest cancers. With an urgent mission to improve outcomes for pancreatic cancer patients and double survival by 2020, the organization, founded in 1999, executes a bold and comprehensive strategy to Wage Hope through research, patient services, advocacy and community engagement. The organization’s visionary goals, world-class programs and services, extensive grassroots network, patient-focused outcomes and advisory board of scientific and medical leaders, provide the critical backdrop to help pancreatic cancer patients today and create transformational change for all patients in the future.
About the Lustgarten Foundation
The Lustgarten Foundation is America’s largest private funder of pancreatic cancer research. Based in Woodbury, N.Y., the Foundation supports research to find a cure for pancreatic cancer, facilitates dialogue within the medical and scientific community, and educates the public about the disease through awareness campaigns and fundraising events. Since its inception, the Lustgarten Foundation has directed $154 million to research and assembled the best scientific minds with the hope that one day, a cure can be found. Thanks to separate funding to support administrative expenses, 100 percent of every dollar donated to the Foundation goes directly to pancreatic cancer research. For more information, please visit www.lustgarten.org.
About the Thyroid, Head and Neck Cancer (THANC) Foundation
The Thyroid, Head and Neck Cancer (THANC) Foundation was incorporated in 2003 and quickly became the largest private funder of research in the United States for these types of cancer. THANC is committed to supporting research and education in the early detection and treatment of thyroid and head and neck cancer, to advancing new therapies, and to alleviating the suffering and functional impairment of patients who undergo treatment.
About Interpace Diagnostics Group, Inc.
Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular and related first line diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® (currently ThyGeNEXT™) for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDx™, that differentiates lung cancer of primary vs. metastatic origin. BarreGEN®, for Barrett's Esophagus, is currently being “soft launched” with key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as important clinical information. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US, and over time can progress to esophageal cancer. The Company’s data base includes data from over 45,000 patients who have been tested using the Company’s current products, including over 15,000 molecular tests for thyroid nodules. Interpace has been designated by CIO Applications magazine as one of the top 20 companies for providing bioinformatics solutions. Interpace’s mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace’s website at www.interpacediagnostics.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company’s history of losses, the Company's ability to adequately finance the business, the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability to maintain its NASDAQ listing. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company's SEC filings, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 23, 2018, Quarterly Reports on Form 10-Q and other SEC filings. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.